Secondary prevention of arterial disease in very elderly people: Results from a prospective registry (FRENA)

Angiology

Volumn 59, Issue 4, 2008, Pages 427-434

  López Jiménez, Luciano ^a   Camafort, M ^h   Tiberio, Gregorio ^c   Carmona, José Antonio ^d   Guijarro, Carlos ^e,h   Martínez Peñalver, Francisco ^f   Monreal, Manuel ^g   Carmona, J A ^h   Ceballos, A ^h   Coll, R ^h   Monreal, M ^h   Pascual, M T ^h   Sanclemente, C ^h   Surinach J M ^h   Toril, J ^h   Lopez Jimenez L ^h   Martinez F ^h   Tiberio, G ^h  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Hospital Comarcal Mora d'Ebre   (Spain)

^c Universidad Pública de Navarra   (Spain)

^d HOSPITAL ALTO GUADALQUIVIR   (Spain)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h Hospital Universitari Germans Trias I Pujol ^*

Author keywords

Outcome; Peripheral arterial disease; Secondary prevention

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN;

ADULT; AGED; AGING; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC LUNG DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; REGISTER;

EID: 49649084211     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319707309299     Document Type: Article

References (12)

1. Knight EL, Glynn RJ, Levin R., Ganz DA, Avorn J. Failure of evidence-based medicine in the treatment of hypertension in older patients. J Gen Intern Med. 2000 ; 15: 702-709.
2. Castilla-Guerra L., Fernández-Moreno MC, Espino-Montoro A., López-Chozas JM, Jiménez MD Prevención secundaria del ictus en pacientes muy ancianos. Rev Neurol. 2006 ; 43: 124-125.
3. Courville KA, Lavie CJ, Milani RV Lipid-lowering therapy for elderly patients at risk for coronary events and stroke. Am Heart Hosp J. 2005 ; 3: 256-262.
4. Hobi A., Roy S., Vuille C., Perdrix J., Darioli R. Evolution of cardiac risk factors management among patients aged 65 and older with coronary artery disease. Rev Med Suisse. 2006 ; 2: 658-663.
5. Dormandy JA, Rutherford B. ; and TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). Management of peripheral arterial disease (PAD). J Vasc Surg. 2000 ; 31: 1S - 96S.
6. Williams MA, Fleg JL, Ades PA, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > 75 years of age). An American Heart Association Scientific Statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation. 2002 ; 105: 1735-1743.
7. Cournot M., Cambou JP, Quentzel S., Danchin N. Reasons for the underuse of secondary prevention therapies in coronary patients over the age of 70 years. Ann Cardiol Angeiol. 2005 ; 54 (suppl 1). S17 - S23.
8. Aronow WS Treatment of older persons with hypercholesterolemia with and without cardiovascular disease. J Gerontol A Biol Sci Med Sci. 2001 ; 56: M138 - M145.
9. Shepherd J., Blauw GJ, Murphy MB, et al. Prospective study of Pravastatin in the elderly at risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2003 ; 260: 1623-1630.
10. Wachtell K., Lehto M., Gerdts E., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005 ; 45: 712-719.
11. Schrader J., Lüders S., Kulschewski A., et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomised controlled study (MOSES). Stroke. 2005 ; 36: 1218-1224.
12. Strandberg TE Secondary prevention of stroke is important: but all hypertensive drugs are not created equal ? Stroke. 2005 ; 36: 1225-1226.